biosimilars

Regeneron’s golden goose Eylea may stave off biosimilar competition until 2024 or beyond
Endpoints
Tue, 05/4/21 - 10:39 am
Regeneron
Eylea
biosimilars
macular degeneration
New laws address NCE exclusivity, biosimilar education
RAPS.org
Mon, 04/26/21 - 10:59 pm
Joe Biden
legislative
regulatory
biosimilars
NCE
Roche sees a slight dip in Q1 as biosim­i­lars keep bit­ing in­to block­buster on­col­o­gy tri­o's sales
Endpoints
Wed, 04/21/21 - 10:40 am
Roche
earnings
biosimilars
Insurance, physician barriers impede wider adoption of biosimilars
RAPS.org
Mon, 04/12/21 - 11:02 pm
biosimilars
physicians
insurance
Biogen adds a late-stage prospect to its growing biosimilar business
BioPharma Dive
Thu, 04/8/21 - 07:44 pm
Biogen
Actemra
anti-inflammatories
biosimilars
COVID-19
Pfizer halts biosimilar programs in crowded China market, sells plant to WuXi Biologics
Fierce Pharma
Wed, 03/17/21 - 11:39 pm
Pfizer
China
biosimilars
WuXi Biologics
Generics companies face risk as SCOTUS questions patent tribunal’s constitutionality
MedCity News
Fri, 03/5/21 - 10:24 am
generics
Supreme Court
patents
biosimilars
devices
The Biosimilar Landscape: An Overview of Regulatory Approvals by the EMA and FDA
Drug Patent Watch
Wed, 02/3/21 - 10:52 pm
regulatory
biosimilars
Europe
EMA
FDA
The More You Know: FDA Provides Additional Guidance on Biosimilars
FDA Law Blog
Wed, 12/16/20 - 10:57 am
FDA
biosimilars
Roche yields to cancer biosim competition by offering 'relevant' discounts: report
Fierce Pharma
Thu, 12/10/20 - 07:19 pm
Roche
biosimilars
CMS
discounts
buy-and-bill
Samsung Biologics, AstraZeneca to dissolve biosimilar JV, scrap Rituxan copy program: report
Fierce Pharma
Thu, 11/19/20 - 08:29 pm
Samsung BioLogics
AstraZeneca
Rituxan
Roche
biosimilars
Archigen Biotech
FDA begins review of Samsung Bioepis/Biogen’s Lucentis biosimilar
Pharmaforum
Thu, 11/19/20 - 10:33 am
Novartis
Genentech
Lucentis
biosimilars
Samsung Bioepis
Biogen
FDA
Testing requirements are likely slowing biosimilar entries in the US
RAPS.org
Wed, 10/14/20 - 05:53 pm
biosimilars
regulatory
patents
drug rebates
Sandoz working to overcome barriers to greater biosimilars uptake in US
Biopharma Reporter
Mon, 09/21/20 - 10:55 am
Sandoz
biosimilars
Novartis
Biocon and Mylan Launch Semglee; Biosimilar, Interchangeable Status Are Sought
Center for Biosimilars
Tue, 09/1/20 - 10:44 am
Biocon
Mylan
Semglee
generics
insulin
diabetes
biosimilars
Pfizer's Unheralded Franchise That's Worth Billions of Dollars
Motley Fool
Sun, 08/16/20 - 10:44 pm
Pfizer
biosimilars
Humira
Inflectra
Remsima
Remicade
autoimmune disease
JNJ
Amgen's Enbrel Patents to Be Upheld Through 2029
Motley Fool
Thu, 07/2/20 - 12:15 am
psoriasis
rheumatoid arthritis
Enbrel
Novartis
biosimilars
patents
AbbVie's Humira defense may keep prices high, but it's still legal, judge rules
Fierce Pharma
Tue, 06/9/20 - 12:11 pm
AbbVie
Humira
biosimilars
patents
Most big commercial health plans rarely prefer biosimilars
Beckers Hospital Review
Thu, 05/21/20 - 10:23 am
insurers
biosimilars
COVID-19 restrictions send generic drug shipping costs through the roof: survey
Fierce Pharma
Sat, 05/2/20 - 11:21 pm
COVID-19
generics
biosimilars
drug manufacturing

Pages